Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients
CAMBRIDGE, Mass. , Jan. 2, 2024 /PRNewswire/ — Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that enrollment has been completed in the randomized controlled Part C of the DisTinGuish study evaluating DKN-01, Leap’s anti-Dickkopf-1 (DKK1) antibody, in combination with tislelizumab, BeiGene’s anti-PD-1 antibody, and chemotherapy in patients with advanced gastroesophageal junction and gastric cancer.
Related news for (LPTX)
- Don’t Miss Out: MoBot’s Latest Stock Updates 10/02/25 03:00 PM
- MoBot alert highlights: NASDAQ: CIGL, NASDAQ: YYAI, NYSE: BURU, NYSE: BBBY, NASDAQ: LPTX (10/02/25 02:00 PM)
- MoBot alert highlights: NASDAQ: STFS, NASDAQ: ABCL, NASDAQ: LPTX, NASDAQ: BNAI, NASDAQ: TTNP (10/01/25 07:00 PM)
- MoBot’s Stock Market Highlights – 10/01/25 06:00 PM
- 24/7 Market News Snapshot 25 September, 2025 – Leap Therapeutics, Inc. Common Stock (NASDAQ:LPTX)